Researchers propose using phages—viruses that naturally infect bacteria—as a platform to hijack the immune memory generated by vaccines, redirecting it to target and destroy cancerous cells. The concept, detailed in New Scientist, relies on genetically modifying phages to display tumor antigens alongside vaccine-derived immune triggers.
This approach exploits the body's existing immunity from routine vaccinations, potentially eliminating the need for personalized cancer therapies. If successful, it could turn widespread vaccine-induced immunity into a ready-made weapon against diverse cancer types, offering a low-cost, scalable treatment strategy.
The phages would be engineered to carry molecular markers from both a common vaccine and a tumor, training the immune system to attack cancer cells bearing those markers. Early experiments in cell cultures and animal models have shown promise, though human trials have not yet begun.
If proven safe and effective, the technique could transform cancer immunotherapy by leveraging pre-existing immunity rather than building new responses from scratch. Patients might receive phage injections to trigger a rapid, targeted immune attack on tumors without the complexity of current cell-based therapies.
Experts caution that the approach remains experimental, with significant hurdles in delivery, tumor specificity, and avoiding autoimmune reactions. The work is at an early preclinical stage.